Zhang Song, Xu Bo, Zhang Ji-Ling, Liu Shun-Hai, Xiang Xin, Liu Pan
Department of Hepatic-Biliary-Pancreatic Surgery, The Fourth People's Hospital of Neijiang, Sichuan, China.
Department of Hepatic-Biliary-Pancreatic Surgery, The First People's Hospital o Neijiang, Sichuan, China.
Medicine (Baltimore). 2024 Dec 13;103(50):e40823. doi: 10.1097/MD.0000000000040823.
Long noncoding RNA (lncRNA) is a significant component of the noncoding genome and refers to RNA molecules that exceed 200 nucleotides in length. It plays a crucial role in both promoting and suppressing cancer by regulating the proliferation, invasion, and metastasis of tumor cells. We have found a correlation between cancer susceptibility candidate 11 (CASC11) experssion and tumorigenesis development prognosis in a number of studies on tumors. Hence, this meta-analysis was conducted to further investigate the effects of CASC11 expression on clinicopathological features and outcome. Furthermore, CASC11 can act both as a therapeutic target and a cancer biomarker.
We conducted a thorough search of PubMed, Embase, Web of Science, and Cochrane Library to identify all eligible studies until September 20, 2023. These studies examined the potential relationship between the expression levels of CASC11 and survival or the range of pathological feature in cancer patients. The impact of CASC11 expression on overall survival (OS) was evaluated using pooled hazard ratios and 95% confidence intervals (CI). The relationship between CASC11 expression and clinicopathological features was assessed through pooled odds ratios and 95% CI.
A total of 11 studies, involving 660 patients, were examined in this analysis. The results revealed that the overexpression of CASC11 was significantly associated with poor OS (hazard ratios = 2.07, 95%CI = 1.64-2.60) in cancer. Further subgroup analysis demonstrated that the overexpression of CASC11 was consistently linked to poorer OS in diverse types of cancer, including digestive system neoplasm, respiratory neoplasms, and gynecologic tumor.
Overall, this analysis established a strong correlation between CASC11 expression and tumor prognosis, suggesting its potential as a predictive marker for tumor progression in diverse cancer types.
长链非编码RNA（lncRNA）是非编码基因组的重要组成部分，指长度超过200个核苷酸的RNA分子。它通过调节肿瘤细胞的增殖、侵袭和转移，在促进和抑制癌症方面发挥着关键作用。在多项肿瘤研究中，我们发现癌症易感性候选基因11（CASC11）的表达与肿瘤发生发展预后之间存在关联。因此，进行了这项荟萃分析，以进一步研究CASC11表达对临床病理特征和预后的影响。此外，CASC11既可以作为治疗靶点，也可以作为癌症生物标志物。
我们全面检索了PubMed、Embase、Web of Science和Cochrane图书馆，以确定截至2023年9月20日的所有符合条件的研究。这些研究探讨了CASC11表达水平与癌症患者生存率或病理特征范围之间的潜在关系。使用合并风险比和95%置信区间（CI）评估CASC11表达对总生存期（OS）的影响。通过合并比值比和95%CI评估CASC11表达与临床病理特征之间的关系。
本分析共纳入11项研究，涉及660例患者。结果显示，CASC11的过表达与癌症患者较差的总生存期显著相关（风险比=2.07，95%CI=1.64-2.60）。进一步的亚组分析表明，CASC11的过表达在包括消化系统肿瘤、呼吸道肿瘤和妇科肿瘤在内的多种癌症类型中均与较差的总生存期一致相关。
总体而言，本分析确定了CASC11表达与肿瘤预后之间的密切关联，表明其在多种癌症类型中作为肿瘤进展预测标志物的潜力。
